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Abstract 
Background: Carbapenem‑resistant Acinetobacter baumannii is considered a top priority pathogen by the World 
Health Organization for combatting increasing antibiotic resistance and development of new drugs. Since it was 
originally reported in Klebsiella pneumoniae in 2009, the quick spread of the blaNDM‑1 gene encoding a New‑Delhi 
metallo‑beta‑lactamase‑1 (NDM‑1) is increasingly recognized as a serious threat. This gene is usually carried by large 
plasmids and has already been documented in diverse bacterial species, including A. baumannii. Here, we report the 
first detection of a NDM‑1‑producing A. baumannii strain isolated in Benin.
Case presentation: A 31‑year‑old woman was admitted to a surgical unit with a diagnosis of post‑cesarean hema‑
toma. An extensively‑drug resistant A. baumannii strain solely susceptible to amikacin, colistin and ciprofloxacin, and 
resistant to several other antibiotics including ceftazidime, imipenem, meropenem, gentamicin, tobramycin, cef‑
tazidime/avibactam, and sulfamethoxazole‑trimethoprim, was isolated from the wound. Production of NDM‑1 was 
demonstrated by immunochromatographic testing. Whole genome sequencing of the isolate confirmed the pres‑
ence of blaNDM‑1, but also antibiotic resistance genes against multiple beta‑lactamases and other classes of antibiotics, 
in addition to several virulence genes. Moreover, the blaNDM‑1 gene was found to be present in a Tn125 transposon 
integrated on a plasmid.
Conclusions: The discovery of this extensively‑drug  resistant A. baumannii strain carrying blaNDM‑1 in Benin is worry‑
ing, especially because of its high potential risk of horizontal gene transfer due to being integrated into a transposon 
located on a plasmid. Strict control and prevention measures should be taken, once NDM‑1 positive A. baumannii has 
been identified to prevent transfer of this resistance gene to other Enterobacterales. Capacity building is required by 
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Background
Acinetobacter baumannii is an opportunistic nosocomial 
pathogen responsible for a broad range of infections [1]. 
Nosocomial isolates of this bacterium are often resistant 
to almost all currently available antibiotics. Some strik-
ing features of this bacterium, such as its ability to cause 
opportunistic infections, to develop antimicrobial resist-
ance and to survive under adverse environmental con-
ditions, have contributed to its wide dissemination [1]. 
The global spread of carbapenem-resistant A. baumannii 
has been observed and is considered a sentinel event of 
emerging antimicrobial resistance [2].
Carbapenem resistance mechanisms in A. baumannii 
are more commonly mediated by carbapenem-hydrolyz-
ing class D beta-lactamases and less often by class B met-
allo-beta-lactamases [3]. Gram-negative bacteria with 
the New-Delhi metallo-beta-lactamase type-1 (NDM-1), 
encoded by the blaNDM-1 gene, utilize at least one zinc 
atom at the active site to facilitate hydrolysis of a broad 
variety of beta-lactams and carbapenems [4]. The initial 
case detection of NDM-1 production was reported in 
2009 in a clinical urinary isolate of Klebsiella pneumoniae 
from a 59-year-old man who returned to Sweden after 
hospitalization in India [5]. Afterwards, the genetic con-
text of blaNDM-1 was reported in 2011 in a clinical A. bau-
mannii isolate discovered in a German hospital [6]. The 
blaNDM-1 gene was integrated on a new transposon struc-
ture (Tn125) flanked by two insertion elements [6]. Sub-
sequently, Tn125-harboring blaNDM-1 was reported on 
chromosomes in several multiple-resistant Acinetobacter 
spp. isolates throughout Europe [7]. Moreover, a blaNDM-1 
bearing plasmid, pNDM-BJ01, was reported in 2012, iso-
lated from a clinical Acinetobacter lwoffii strain in China 
[8]. This plasmid carried a complete Tn125 transposon 
and showed high horizontal transferability. Since then, 
several NDM-1 positive plasmids have been isolated 
from Acinetobacter spp. in China with similar structures 
to pNDM-BJ01 [9]. To date, NDM carbapenems have 
been reported in most regions around the world owing 
to the rapid dissemination of the gene between mem-
bers of the Enterobacterales and Acinetobacter spp. in 
human and environmental isolates [1]. So far, only lim-
ited reports exist on NDM-1 producing A. baumannii in 
Africa, and those published are mostly from northern or 
southern African countries [10, 11]. Here, we describe 
the first case of an extensively drug-resistant A. bauman-
nii strain producing NDM-1- in Benin.
Case presentation
A 31-year-old woman was admitted to a surgical unit 
at a public hospital in Benin on March 06, 2019. She 
had undergone a ceasarean in a different hospital and 
presented hematoma, but previous treatment informa-
tion and conditions were not recorded upon admission. 
During laparotomy, surgical antimicrobial prophylaxis 
was administered as intravenous ceftriaxone (1 g), and 
after intervention, empirical antibiotic therapy consist-
ing of intravenous imipenem (500  mg every 8  h) was 
initiated for one week. On the tenth day, the patient’s 
clinical condition worsened and she developed fever 
(38 °C) and wound suppuration. Preliminary investiga-
tion revealed that the patient had no previous history 
of travel or hospitalization abroad. Intensive programs 
of environmental cleaning and strict contact isolation 
precautions were applied. However, following the initial 
treatment of 500 mg imipenem per 8 h, the patient pre-
ferred to continue with unspecified indigenous treat-
ment due to lack of financial support. As she was no 
longer in the hospital, the clinical outcome is unknown.
The culture of a pus swab revealed Gram-negative 
coccobacilli that were glucose-non-fermentative, non-
motile, and oxidase-negative. Biochemical identifica-
tion was performed with the Analytical Profile Index 
(API 20E, Biomérieux, France) and results were con-
firmed by matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometry. Anti-
microbial susceptibility testing was assessed using the 
modified Kirby-Bauer disc diffusion method and con-
firmation was done by the microbroth dilution method. 
The interpretation breakpoints were based on the crite-
ria of the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) (http://www.eucas t.org/
ast_of_bacte ria/). Except for amikacin, colistin and cip-
rofloxacin, the isolate was resistant to all tested antimi-
crobial agents with the following Minimum Inhibitory 
Concentration (MIC) values: ceftazidime (> 16  mg/l), 
imipenem and meropenem (> 16 mg/l), gentamicin and 
tobramycin (> 8  mg/l), ceftazidime/avibactam (> 16/4), 
sulfamethoxazole-trimethoprim (> 8/152). The isolate 
was therefore considered as extensively drug resistant 
(XDR) [4]. Additionally, to confirm the resistance pat-
tern, we used the multiplex lateral flow immunochro-
matographic test, the RESIST-3 O.K.N. ICT (Coris 
Bioconcept, Gembloux, Belgium), which confirmed the 
presence of NDM.
governmental agencies to provide suitable antibiotic treatment options and strategies, in combination with strength‑
ening laboratory services for detection and surveillance of this pathogen.
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Page 3 of 7Yehouenou et al. Ann Clin Microbiol Antimicrob            (2021) 20:5  
Whole-genome sequencing (WGS) was subsequently 
performed for detection and characterization of resist-
ance genes, using DNA from a single-colony isolate 
employing the EZ1 advanced XL biorobot and the 
tissue DNA kit (Qiagen, Hilden, Germany) with the 
bacterial card, according to the manufacturer’s instruc-
tions. A standard Nextera XT library (Illumina, San 
Diego, USA) was constructed (Nextera XT DNA library 
preparation kit, Illumina, San Diego, USA) and subse-
quently sequenced on an Illumina MiSeq instrument 
with a 250-bp paired-end protocol (MiSeq v3 chemis-
try, Illumina, San Diego, USA) according to the manu-
facturer’s instructions. Data was analyzed as follows. 
First, reads were trimmed with Trimmomatic 0.36 [12] 
with the settings ‘NexteraPE-PE.fa:2:30:10’, ‘LEAD-
ING:10’, ‘TRAILING:10’, ‘SLIDINGWINDOW:4:20’, 
and ‘MINLEN:40’. Processed reads were then assem-
bled de novo using SPAdes 3.13.0 [13] with the ‘care-
ful’ option enabled and the ‘cov-cutoff ’ parameter set to 
10. Contigs smaller than 1000 bases were removed with 
seqtk seq  1.2 (https ://githu b.com/lh3/seqtk ) using the 
‘-L’ option. Assembly statistics were determined using 
Quast 4.4 with default settings [14]. Genome annota-
tions were created using Prokka 1.13 [15] (Table 1).
The NCBI National Database of Antibiotic Resist-
ant Organisms (NDARO) [16], Virulence Factor (full) 
database (VFDB) [17], and PlasmidFinder database, 
were used for genotypic detection of genes encoding 
antimicrobials, virulence factors, and plasmid repli-
cons, respectively, using SRST2 0.2.0 [18] with default 
settings. The XDR status of the isolate was confirmed 
by harboring several resistance genes against aminogly-
cosides (aph(6)-Id, aph(3”)-Ib, ant(3’’)-IIa, and aac(3)-
IId), beta-lactamases (blaNDM-1, blaOXA-58, blaOXA-558, 
blaADC-166), macrolide-lincosamide-streptogramin B 
(msr(E)), macrolide (mph(E)), sulfonamide (sul2), tetra-
cycline (tet(39)), and bleomycin (ble). Additionally, 67 
loci encoding different virulence factors were detected 
including genes related to biofilm formation such as 
ompA, bfmS, csuE, and a K1 capsular polysaccharide 
(ABK1) (see Additional file  1). No plasmid replicons 
from the PlasmidFinder database were detected.
Sequence typing was performed with the corre-
sponding regular multi-locus sequence typing (MLST) 
schemes from Oxford University and Institut Pasteur 
[19], as described in Bogaerts et  al. [20]. MLST anal-
ysis detected sequence type 836 (Oxford University 
scheme) and 388 (Institut Pasteur scheme). No isolates 
were present for the former, but the latter returned 
two isolates from Taiwan (from 2012 and 2013) and 
a single isolate from Norway (year unknown) with 
the same sequence type. The sample was screened 
for the presence of the Tn125 transposon by mapping 
(trimmed) reads against its reference sequence (NCBI 
KF702386.1) using Bowtie2 2.3.0 [21] with the ‘–sen-
sitive’ setting enabled. In total, 99.55% of the Tn125 
transposon reference length of 10,624 bp was covered 
by at least one read, with three breakpoints however 
present at ~ 7.7 kb, 8.5 kb, and 9.2 kb, indicating some 
minor rearrangements. The median depth of cover-
age of the Tn125 transposon was 98.20× (compared 
to 83.0X for the whole genome). The alignment and 
annotation for the Tn125 transposon are visually rep-
resented in Fig. 1. An additional de novo assembly was 
then performed using plasmidSpades 3.13.0 with the 
‘-plasmid’ and ‘-careful’ options enabled [22] to recon-
struct putative plasmids. This resulted in 21 contigs, 
with the blaNDM-1 gene located near the center of the 
largest contig (88,063  bp) and its surrounding region 
of 7626  bp aligned to the Tn125 transposon with 
over 99% sequence identity. Outside of this region, 
no alignments were found between this putative plas-
mid contig and the pNDM-BJ01 (NCBI NC_019268.1) 
plasmid. Additional screening of the putative plasmid 
contig against the Plasmid Database (PLSDB) online 
platform [23] (v2020_03_04) with mash was therefore 
performed and provided four matches: a large plasmid 
of 78,125 bp (NCBI CP038501.1) that was found in A. 
baumannii, and three smaller ones (NCBI JQ739158.1, 
KF220658.1, KR059864.1) with sizes 4797, 1634 
and 7865  bp, respectively. Alignments with BLAST 
Table 1 Genome assembly, and putative plasmid, statistics
This table contains statistics for the de novo assembly and annotation of the genome and putative plasmid. The number of coding sequences and tRNAs were 




Nb. of contigs GG-content (%) Nb. of coding 
sequences
Nb. of tRNAs NCBI accession
Genome assembly 4,082,860 39 38.92 3838 64 JABBFT000000000
Putative plasmid 88,063 1 42.13 101 0 JABBFT000000000 
(Seqeuence ID: 
Sciensano:GLGAKIBC_35)
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showed that the majority of the putative plasmid con-
tig carrying blaNDM-1 aligned to regions on the larger 
CP038501.1 plasmid (albeit with several rearrange-
ments), except for the region containing the sequence 
that aligned to the Tn125 transposon as illustrated in 
Fig.  2. The three smaller plasmid matches all corre-
sponded to parts of the Tn125 transposon (results not 
shown).
Fig. 1 Detection of the Tn125 transposon carrying the blaNDM‑1 gene. The top half of the figure contains the genomic coordinates and annotation 
of the Tn125 transposon sequence retrieved from NCBI (KF702386.1). The lower half of the figure contains the sequencing depth and reads mapped 
to the corresponding regions. Visualization created with IGV [29]
Fig. 2 Alignment of the putative plasmid containing blaNDM‑1 against the CP038501.1 plasmid. The figure illustrates the putative plasmid generated 
with plasmidSPAdes aligned to the CP038501.1 plasmid that was detected as best match with PLSDB. The location of blaNDM‑1 on the putative 
plasmid is indicated in orange. High‑quality alignments between the putative plasmid and CP038501.1 are indicated in blue (with darker blue 
representing higher BLAST bit scores). The left and right plots illustrate the alignments in normal frame (plus strand/plus strand) and reverse frame 
(plus strand/minus strand), respectively. Visualization created with Kablammo [30]
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Discussion and conclusion
To the best of our knowledge, we present the first 
description of a NDM-1 producing A. baumannii iso-
lated in Benin. In particular, we detected the Tn125 
transposon that harbors the blaNDM-1 gene on a contig of 
88,063 bp. Because this contig was generated with plas-
midSpades and a search against PLSDB demonstrated 
high similarity to the CP038501.1 plasmid previously 
reported in A. baumannii but not carrying the blaNDM-1 
gene, our results indicate that most likely a plasmid simi-
lar to CP038501.1 obtained the blaNDM-1 gene through 
the integration of the Tn125 transposon. In particular, 
the horizontal transfer capacity of this transposon in 
relationship with genes encoding NDM has been previ-
ously demonstrated within Acinetobacter and also other 
bacteria [24, 25]. Moreover, the strain showed an XDR 
pattern with resistance against several other antibiotics 
confirmed both by phenotypical testing and the detec-
tion of several other resistance genes, thereby limiting 
therapeutic options. Accordingly, A. baumannii clinical 
isolates usually exhibit multidrug resistance phenotypes, 
facilitating their persistence in hospital settings [26]. The 
ease of availability of antibiotics is probably one of the 
biggest contributors to antibiotics resistance. Especially 
in developing countries, there is little regulation on the 
retail of pharmaceuticals. Moreover, the strain harbored 
several virulence genes related to biofilm formation. Bio-
film formation in A. baumannii has been suggested to 
decrease the diffusion of drugs through the bacterial cells 
leading to multidrug resistance and also aids the strong 
survival ability of A. baumannii in harsh environments 
[26].
Low- and middle-income countries suffer a lack of 
infrastructure and resources to monitor AMR and 
perform optimal antibiotic treatment. For instance, 
cefazolin is the recommended antibiotic for surgical 
antimicrobial prophylaxis (SAP), but unfortunately 
this antibiotic is unavailable in Benin. The use of broad 
spectrum cephalosporins such as ceftriaxone in SAP 
is even more likely to induce resistance than cefazo-
lin and other widely used surgical prophylactic drugs. 
Treatment options are limited for patients infected 
with XDR strains, increasing the severity of such infec-
tions. In this case, the XDR strain was only suscepti-
ble to amikacin, ciprofloxacin and colistin. Amikacin 
is however only available for one case out of two in 
Benin. Clinicians are often forced to buy it from neigh-
boring countries such as Nigeria or Togo. Novel treat-
ments effective against NDM-producing A. baumannii 
isolates are limited, and reduced activity was observed 
for strains that produced particular types of other beta-
lactamases such as oxacillinases [27]. Moreover, Benin 
does not have the necessary quality assurance mecha-
nisms to ensure that antibiotics being supplied are of 
high quality. Knowledge of the occurrence of NDM-1 
producing bacteria may encourage pharmaceutical 
companies and the Ministry of Health to facilitate the 
provision of ‘last-resort’ antibiotics. Innovative thera-
peutic strategies such as bacteriophage therapy and 
monoclonal antibodies, or soon-to-be commercially 
available antibiotics such as plazomicin or cefiderocol, 
should also be considered for future use [27].
The threat of increasing antibiotics resistance is not 
limited to A. baumannii. For instance, methicillin-
resistant Staphylococcus aureus and extended-spec-
trum beta-lactamase producing organisms are also 
frequently detected in certain public teaching hospitals. 
Our laboratories need to be better resourced so that 
they can deliver antibiotics susceptibility information. 
This includes equipment, consumable resources and 
their supply chain, as well as development of the nec-
essary human resources to perform tests, store, curate 
and disseminate data [28]. Unfortunately, phenotypic 
detection of carbapenemase-producing bacteria is not 
routinely performed. The immunochromatographic 
RESIST-3 O.K.N. ICT test that can detect the presence 
of NDM enzymes, represents a cost-effective alterna-
tive to costlier and less widely available characteriza-
tion methods that rely on molecular amplification.
In conclusion, the isolation of this XDR A. bau-
mannii strain containing genes encoding NDM-1 and 
other beta-lactamases is worrying. The presence of 
blaNDM-1 located on the Tn125 transposon integrated 
in a plasmid represents a serious threat because of its 
potentially high horizontal transferability. Carbapene-
mase-producing XDR bacteria can be fatal in resource 
limited countries where therapeutic antibiotic options 
are restricted. Through this study, we want to alarm 
the official and governmental agencies to contribute 
to strengthening laboratory services and equipment 
at both the local and national level, and urge them to 
make arrangements for the provision of drugs such as 
avibactam combinations in Benin. Additionally, further 
efforts to characterize the molecular structure of this 
plasmid will aid to assess its transferability and hence 
risk of spread in the overall population, as well as ben-
efit developing targeted detection methods for surveil-
lance at the population level.
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Additional file 2. Virulence factor database (VFDB) of A.baumannii 
NDM‑1.
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